Influenza challenge virus
PreclinicalBiologic
Influenza challenge virus is one of 36 biologic programs targeting Influenza. It is currently in Preclinical.
1
Indications
2
Total Trials
1
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
95 competitors in Influenza
#DrugCompanyPhaseTrials
1Influenza Vaccine
NovartisPhase 3
FLU Vaccine
GSKPhase 3
Inactivated Influenza Vaccine
SanofiPhase 3
Seasonal Influenza Vaccine
NovartisPhase 3
Live Attenuated Zoster Vaccine
CChangchun BCHT Biotechnology Co.
Phase 3
COVID-19 Vaccine
ModernaPhase 2
Relenza
GGlaxo Dba Glaxosmithkline
Phase 3
VAXIGRIP
GSKPhase 3
Dexametasone
UUniversity of Malaya
Phase 3
GP681
JJiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Influenza challenge virus. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Biologic[2]
- Highest Phase
- Preclinical[1]
- Company
- IImperial College London